611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Rogue Genes May Cause Some ALS CasesSticky Brain 'Plaques' Implicated in Alzheimer's AgainEven Your Bones Can Get Fat, Mouse Study SuggestsDoes a Low-Fat Dairy Habit Boost Parkinson's Risk?MicroRNA Biomarker Signature Identified for Allergic AsthmaHaywire Immune Cells May Help Cause BaldnessRegion in Brain Associated With Fear of Uncertain FutureBrain Scans Spot Where Fear and Anxiety LiveGene Therapy Might Someday Mend Badly Broken BonesLife Expectancy Slighter Shorter With Parkinson's, DementiaStudy Looks at Parkinson's Effect on Life SpanBody Cooling May Help Brain After Cardiac ArrestDo You Overeat? Your Brain Wiring May Be WhyGene Mutation May Speed Alzheimer's DeclineIs This Enzyme Making You Fat?Type 2 Diabetes May Be Bad for Brain Health'Brain Age' May Help Predict When You'll DieParkinson's Disease May Originate in Gut, Study SaysBlood-Based Genome Testing Feasible for Rapid Mutation AssayBlood Test May Gauge Death Risk After Surgery150-Year-Old Drug May Shorten 'Off' Time for Parkinson's PatientsBrain May Be Organized by Functions, Not Body PartsBody Temperature Might Give Clues to ComaCould Young Blood Boost the Aging Brain?A 'Brainwave' to Help Fight PTSDDizziness in Parkinson's May Be Due to Cerebral HypoperfusionMisunderstood Gene Tests May Lead to Unnecessary MastectomiesScientists Extend Lives of Mice With ALSFDA Approves 1st Direct-to-Consumer Genetic Risk TestsFDA OKs 1st At-Home Genetic Tests for 10 Disorders'SuperAgers' Have Less Whole-Brain Cortical Volume LossHigh Thyroid Hormone Levels Tied to Stiffer ArteriesBrain Changes May Mark Risk of Financial Exploitation in SeniorsRegular Exercise Slows Decline Even in Advanced Parkinson's DzBrain-Computer Link Restores Some Movement to Quadraplegic ManScientists Spot Gene for Rare Disorder Causing Deafness, BlindnessNew Technology Makes Gene Mapping Cheaper, Faster: StudyTurning Back the Aging Clock -- in MiceNew Parkinson's Drug Xadago ApprovedBrain 'Rewires' to Work Around Early-Life BlindnessBrain Training for Cancer Survivors' Nerve DamageASA: Vagus Nerve Stimulation May Enhance Stroke RecoveryGene Therapy: A Breakthrough for Sickle Cell Anemia?Gene Therapy Shows Promise for Aggressive LymphomaThe Brain Can Produce Its Own Sugar: ReportCould Parkinson's Disease Raise Stroke Risk?NHL Veterans Pledge Their Brains to ResearchMRIs Can Be Safe for People With Heart Devices …Scientists Shed Light on Possible Cause of NearsightednessBrain Chip Helps Paralyzed 'Type' With Their Mind
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Researchers Develop Potential Oral Treatment for Hemophilia

HealthDay News
by -- Robert Preidt
Updated: Dec 29th 2016

new article illustration

THURSDAY, Dec. 29, 2016 (HealthDay News) -- People with hemophilia have to endure painful injections every few days to stay alive, but a newly developed treatment may one day offer a simpler, cheaper and less painful alternative.

University of Texas at Austin researchers created an oral treatment for one type of hemophilia, which is a serious, genetic bleeding disorder. But, the treatment is still in the early stages of development, and it's not yet clear when -- or if -- the encapsulated therapy will be in clinical trials.

About 400,000 people worldwide have either hemophilia A or B, both of which are caused by a missing protein in the blood.

In many parts of the world, access to treatment for hemophilia is limited by cost, the need for trained health workers, and the risk of complications associated with injection drug therapy.

The new capsule has nanoparticles that carry a protein therapy to treat hemophilia B. This type of hemophilia is caused by a missing or defective clotting protein called factor IX, the research team said.

The treatment is encapsulated, allowing it to pass through the stomach without being destroyed by gastric enzymes. It isn't until the capsule reaches the small intestine that it begins to swell and degrade. As the capsule degrades, the treatment is slowly released, the researchers explained.

"While an oral delivery platform will be beneficial to all hemophilia B patients, patients in developing countries will benefit the most," study lead author Sarena Horava said in a university news release.

"In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy," Horava said.

The capsule is still in development and further tests are required before clinical trials can be considered.

The researchers described their new treatment recently in the International Journal of Pharmaceutics.

More information

The U.S. National Library of Medicine has more on hemophilia.